
Medicine and Health
Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
N. Snelder, R. Heinig, et al.
Explore how finerenone, a groundbreaking selective mineralocorticoid receptor antagonist, has been meticulously characterized through population pharmacokinetics and pharmacodynamics studies. This innovative research by Nelleke Snelder, Roland Heinig, and their team illuminates the efficacy and safety markers vital for reducing albuminuria in patients with type 2 diabetes and chronic kidney disease.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.